Capital Increase invendo medical
CFP BioConnect advised invendo medical, a developer of an innovative sterile, single-use colonoscope on a EUR 4.5 million (USD 6 million) financing round, co-led by Wellington Partners and TVM Capital. Existing shareholder Heidelberg Innovation also participated in this financing, wich will allow invendo to complete the development of the invendoscope™ through regulatory approval in the US.
In contrast to established colonoscopes in clinical use today, invendo’s patented device is sterile and for single use only. The invendosope™ combines a highly flexible endoscope shaft and the proprietary “inverted sleeve” technology that enables a highly safe and potentially painless colonoscopy procedure without sedation. invendo’s colonoscope is CE-marked in Europe. Market launches in Europe and in the US are expected in 2010.
Corporate Finance Partners acted as an exclusive adviser to invendo medical.
In contrast to established colonoscopes in clinical use today, invendo’s patented device is sterile and for single use only. The invendosope™ combines a highly flexible endoscope shaft and the proprietary “inverted sleeve” technology that enables a highly safe and potentially painless colonoscopy procedure without sedation. invendo’s colonoscope is CE-marked in Europe. Market launches in Europe and in the US are expected in 2010.
Corporate Finance Partners acted as an exclusive adviser to invendo medical.
